gptkbp:instance_of
|
gptkb:drug
|
gptkbp:bfsLayer
|
3
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
gptkbp:activities
|
TNF-alpha inhibitor
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
gptkbp:brand
|
infliximab
|
gptkbp:class
|
gptkb:monoclonal_antibody
gptkb:drug
|
gptkbp:clinical_trial
|
Phase III
Avsola
Inflectra
Renflexis
|
gptkbp:contraindication
|
heart failure
active infections
hypersensitivity to infliximab
|
gptkbp:dosage_form
|
solution for infusion
|
gptkbp:education
|
informed consent required
monitor for signs of infection
|
gptkbp:formulation
|
lyophilized powder
|
gptkbp:frequency
|
every 6 to 8 weeks
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remicade
|
gptkbp:indication
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
|
gptkbp:ingredients
|
infliximab
|
gptkbp:invention
|
gptkb:2018
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
tuberculosis screening
|
gptkbp:is_used_for
|
treatment of autoimmune diseases
|
gptkbp:manager
|
intravenous
|
gptkbp:manufacturer
|
gptkb:Johnson_&_Johnson
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
gptkbp:pharmacokinetics
|
dose-dependent clearance
half-life of 8 to 10 days
inhibition of TNF-alpha
|
gptkbp:population
|
gptkb:Person
adults
|
gptkbp:price
|
high
|
gptkbp:provides_information_on
|
recommended for severe cases
used in combination with methotrexate
|
gptkbp:requires
|
available online
|
gptkbp:research
|
clinical studies
off-label uses
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
gptkbp:side_effect
|
fatigue
headache
nausea
infections
autoimmune disorders
infusion reactions
serious infections
malignancies
|
gptkbp:storage
|
refrigerated
|